36.1 F
New York
Wednesday, January 20, 2021

The Aftermath of Immune Pharmaceuticals Inc (NASDAQ:IMNP) Reverse Split

Must read

Why Is Everyone Talking About Alpine 4 Technologies Ltd (OTCMKTS:ALPP) Stock?

Investors who are looking for fast-moving stocks have had have made options in recent days. One stock that certainly stands out is...

Nano One Materials Corp (OTCMKTS:NNOMF) Signs Cathode Evaluation Agreement: Stock Reacts

Over the past week, there have been many stocks that have managed to generate significant gains and one of those is Nano...

Grayscale Bitcoin Trust (OTCMKTS:GBTC) Extends Rally As Bitcoin Jumps

One of the bigger stories of the year so far has been the massive gains made by Bitcoin. This week BTC hit...

Plyzer Technologies Inc (OTCMKTS:PLYZ) Gains Momentum on High Volume: Now What?

One of the more notable gainers this week on the OTC is Plyzer Technologies Inc (OTCMKTS:PLYZ). The stock was in focus among...

Immune Pharmaceuticals Inc (NASDAQ:IMNP) did a 1–20 reverse stock split last week in a neutral move for shareholders, but announced Thursday they were close to inking a critical agreement with a Latin American partner sending these shares 50%+ higher in recent trading action.

A look at the chart below explains why the stock is trading in this $3.50 to $4 area post reverse and the news.

Immune Pharmaceuticals Inc (NASDAQ:IMNP) announced that it has entered into a letter of intent with Pint Pharma GmnH, a pharmaceutical company focused on Latin America regarding an exclusive license to commercialize Ceplene throughout Latin America and target closing a final agreement within 30 days. Pursuant to the anticipated final agreement, Pint will be responsible for registration of Ceplene in Latin American countries based on the existing European marketing authorization and will carry out the full commercialization of the licensed product in the territory, including Ceplene registration, pricing and reimbursement, and sales and marketing activities.

In conjunction with the anticipated final agreement, Pint will make an investment of $4 million into Immune Pharma’s oncology subsidiary, Cytovia, Inc. to be used by Cytovia exclusively for oncology related activities.

Find out when $IMNP stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Ceplene has been approved in Europe for the maintenance of first remission in patients with Acute Myeloid Leukemia (AML) in combination with interleukin-2 (IL-2). According to Pint, there are approximately 10,000 new cases of AML diagnosed per year in Latin America and there is currently no approved treatment for the maintenance of  AML remission.

“We are excited about the possibility of partnering with Pint Pharma, a market leader in Latin America with strong commercialization capabilities in the field of oncology. Pint Pharma’s desire to bring Ceplene/IL-2 immunotherapy to patients in Latin America  complements our strategy,” said Dr Daniel Teper, CEO of Immune.

“Adding Ceplene to our portfolio of products will further leverage our experience and presence in the oncology field in Latin America,” said David Munoz, Chief Executive Office at Pint. “We are delighted to potentially have Immune as a committed partner to help strengthen our product portfolio.”

Dr. Massimo Radaelli, Executive Chairman of Pint Pharma, has served as an independent director of Ariad Pharmaceuticals Inc. until 2016. He has held the position of President and CEO of Dompe International SA and previously held senior executive positions at Roche, Menarini and DuPont Merck.

“We are very enthusiastic about this potential partnership with Immune and Cytovia which is developing much needed therapies in oncology,” said Dr. Radaelli. “We believe we can leverage the high unmet need for relapse preventive immunotherapy to potentially accelerate the registration and commercial availability of Ceplene in Latin America for patients suffering from AML.”

Ceplene (histamine dihydrochloride) is administered in conjunction with low dose interleukin-2 (IL-2), for maintenance of first remission in patients with Acute Myeloid Leukemia (AML). It has been shown in clinical studies to prevent leukemic relapses in AML patients in first remission and prolong leukemia-free survival while maintaining good quality of life during treatment.  Ceplene acts by enhancing the immunostimulatory effect of IL-2 and countering ROS-induced dysfunction and apoptosis of T and NK cells, thereby inducing immune-mediated killing of leukemic cells, providing a strong rationale for this combination therapy. A recent Phase IV study presented at the meeting of the American Association for Cancer Research in 2016 confirmed the safety and efficacy of Ceplene in the international study that supported European approval.

AML patients receive intensive induction treatment with chemotherapeutic drugs at diagnosis and typically become free of detectable leukemia, achieving “complete remission.” However, within 1-2 years, the majority (75-80%) of adult patients will experience a relapse of leukemia, with a survival prognosis of 33% in younger patients and 15-20% in patients over 60 years of age. According to the American Cancer Society, there will be approximately 21,380 new cases of AML and 10,590 deaths from AML in the US in 2017. The prognosis following first remission is poor and there are no other effective remission therapies currently available. AML represents an orphan condition with high unmet need.

Reverse splits scare some investors, but this one seems well thought out for Immune Pharmaceuticals Inc. (Nasdaq:IMNP), and the potential partnership has created a nice move for the shareholders, but pay attention to your statement because in addition to the move today they had a 1- 20 reverse so you have fewer of these shares, but they are worth significantly more. We will continue to follow IMNP closely – and will update as the color becomes more clear. For continuing coverage on shares of $IMNP stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

Latest article

Signal Advance Inc (OTCMKTS:SIGL) Makes a Big Move, Again.

Speculation and confusion can often lead to strange occurrences on the stock markets and that is what happened...

Ozop Energy Solutions Inc (OTCMKTS:OZSC) Remains Volatile: Stock in Focus

Those who are looking to discover stocks that may have made big moves over the course of the past week could consider...

Data Storage Corp (OTCMKTS:DTST) Gets Sudden Attention: What’s The Buzz?

One of the stocks to have made significant gains this week was that of Data Storage Corp (OTCMKTS:DTST). The Data Storage Corporation...

A Closer Looks at American Battery Metals Corp (OTCMKTS:ABML) Developments

American Battery Metals Corp (OTCMKTS:ABML) is one of the stocks to have been in focus among investors over the course of the...

Why is Grayscale Ethereum Trust (ETH) (OTCMKTS:ETHE) In a Bearish Trend?

The Bitcoin rally over the past weeks has taken the crypto space by storm. However, it should not be forgotten that Ethereum,...